Targeted Cancer Therapy in Melbourne
Targeted therapies are anti-cancer medicines designed to act on particular molecules, proteins or signalling pathways that a cancer depends on. Rather than treating all cancers from the same organ in the same way, targeted treatment uses information about the biology of an individual tumour or blood cancer to identify therapies that are more likely to work for that specific disease.
Northern Blood & Cancer Care provides targeted therapy planning and monitoring for patients across Melbourne. Our medical oncologists and haematologists interpret pathology, biomarker and molecular results, discuss whether a target is clinically meaningful, and coordinate treatment through Northern Private Hospital, Northern Health or a tertiary service when appropriate. Targeted therapy may be used alone or combined with chemotherapy, immunotherapy or hormone therapy, depending on the cancer and treatment setting.
Cancer develops because cells acquire changes that allow them to grow, survive or spread abnormally. Some of these changes create a biological weakness that can be targeted with a medicine. The target may be a receptor on the surface of the cancer cell, an enzyme or signalling pathway inside the cell, a blood-vessel growth pathway or another molecular feature involved in cancer survival.
The term “targeted” does not mean the treatment has no effect on normal tissue. These medicines can still cause important side effects because many targets also have roles in healthy cells. What makes them different is that treatment selection is based more directly on a known biological feature of the cancer rather than only on where the cancer started.
Some cancers are routinely tested for proteins or receptors that can guide treatment. Examples include HER2 in breast and stomach cancers and hormone receptors in breast cancer. The presence, absence or level of a marker can change the treatment plan substantially, which is why a pathology report is often revisited in detail during an oncology consultation.
Tumour DNA or RNA testing can identify gene changes that are potentially targetable. This is particularly important in some lung cancers and increasingly relevant in bowel, prostate, ovarian, melanoma, biliary and other cancers. Testing may be performed on tumour tissue and, in selected situations, on circulating tumour DNA from a blood sample. Not every detected mutation has an effective treatment, and not every available treatment is appropriate for every tumour type.
Many blood cancers are defined by molecular or cell-surface features that can be treated with targeted medicines or therapeutic antibodies. Chronic leukaemias, lymphoma, myeloma and myeloproliferative neoplasms are examples where molecular testing can help confirm the diagnosis, estimate risk or direct therapy. Treatment may be oral, intravenous or combined with other anti-cancer medicines.
Targeted therapy may be combined with another treatment rather than used in isolation. It may be paired with hormone therapy in breast or prostate cancer, with chemotherapy in selected solid tumours and blood cancers, or with immunotherapy in some advanced cancers. The evidence for the specific combination matters, because combining treatments can also increase toxicity.
Some targeted medicines are tablets or capsules taken at home every day or on a defined schedule. Others are given by intravenous or subcutaneous infusion in a day oncology unit. Oral treatment can feel less intensive than an infusion, but it still requires specialist supervision. Dose timing, food requirements, interactions with other medicines and adherence can affect both safety and effectiveness.
Monitoring depends on the therapy. Regular blood tests may assess blood counts, liver and kidney function, electrolytes or other biochemical changes. Some medicines require blood-pressure checks, heart monitoring, skin review or other targeted surveillance. Imaging is used at appropriate intervals to assess whether the cancer is responding.
Side effects depend on the biological pathway being targeted. Possible effects include diarrhoea, skin rash, mouth soreness, fatigue, changes in blood counts, liver-test abnormalities, high blood pressure, fluid retention or effects on heart function. Some treatments can cause bleeding, clotting, wound-healing problems, lung inflammation or other less common complications. Patients are given treatment-specific information because a generic side-effect list is not sufficient for safe care.
Targeted medicines can also interact with prescription drugs, supplements and some foods. It is important that the oncology or haematology team has a complete medication list and is told about any new medicine started during treatment. Dose reductions or temporary interruptions are common tools for managing toxicity and do not automatically mean the treatment has failed.
Cancer cells can change over time and may eventually bypass the pathway a targeted treatment was blocking. When this happens, the specialist reviews the pattern of progression and the treatments already used. Repeat tumour sampling or circulating tumour DNA testing may sometimes identify a new resistance mechanism or another target.
The next step might involve a different targeted therapy, chemotherapy, immunotherapy, hormone therapy, radiotherapy, surgery or a clinical trial. This is one reason modern cancer treatment is often a sequence of decisions rather than a single fixed plan made at diagnosis.
Northern Blood & Cancer Care is particularly well suited to targeted treatment because the team combines tumour-specific clinical expertise with strong academic and research links. This includes experience in precision oncology, circulating tumour DNA, personalised treatment decision-making, tumour-targeting research and clinical trials, alongside clinical and laboratory haematology expertise in molecularly defined blood disorders.
Treatment can be coordinated through day oncology services at Northern Private Hospital or Northern Health when an infusion is required, while many oral targeted therapies are taken at home with scheduled specialist review. Where molecular testing identifies a treatment or trial available only through a tertiary centre, the Northern Blood & Cancer Care team can coordinate referral while remaining involved in ongoing care.
Please bring a current referral, medication list, pathology reports, molecular or genetic test results and relevant imaging. If tumour profiling has already been performed, the complete report is more useful than a brief summary because the significance of a finding can depend on the exact variant, test method and cancer type. Your specialist will explain which results are actionable and which are not currently expected to change treatment.
If targeted therapy is recommended, the discussion should cover the treatment goal, how the medicine is given, likely duration, monitoring, important interactions and the symptoms that should prompt early contact with the treatment team.
A molecular result is only useful when it is interpreted in the context of the cancer, the evidence and the patient. Northern Blood & Cancer Care combines precision-oncology research, laboratory haematology and tumour-specific clinical expertise to identify when targeted therapy is genuinely relevant and to integrate it thoughtfully with the rest of the treatment plan.
Northern Blood & Cancer Care brings together a highly experienced team of haematologists, medical oncologists and specialist physicians, with consultations available at Northern Private Hospital in Epping.
Contact our team to arrange an appointment or discuss a referral.
